Clinical trial
Vorinostat in Treating Patients With Kidney Cancer
NCT00278395 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00278395 |
|---|---|
| Title | Vorinostat in Treating Patients With Kidney Cancer |
| Official title | A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | Vorinostat |
| Enrollment | 14 |
| Start date | Oct 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jan 18, 2006 |
| Last update posted | Nov 14, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: